Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
A phase III, open-label, randomized study of atezolizumab in combination with carboplatin plus paclitaxel plus bevacizumab compared with pemetrexed plus cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
- Authors
- Park, Sehhoon; Lee, Yun-Gyoo; Park, Ji Hyun; Lee, Gyeong-Won; Kang, Eun Joo; Choi, Yoon Ji; Shin, SeongHoon; Han, Ji-Youn; Lee, Suee; Kim, YuJung; Kim, Tae Min; Kim, Sang-We; Shim, Byoung Yong; Cho, Jinhyun; Kim, Hye Sook; Park, Sang Gon; Lee, Ki Hyeong; Kim, Ilhwan; Ahn, Myung-Ju
- Issue Date
- 20-May-2020
- Publisher
- American Society of Clinical Oncology
- Citation
- Journal of Clinical Oncology, v.38, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Clinical Oncology
- Volume
- 38
- Number
- 15
- ISSN
- 0732-183X
1527-7755
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.